Trials / Recruiting
RecruitingNCT06451497
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Toripalimab in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Zumutor Biologics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
Conditions
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Pancreas Adenocarcinoma
- Biliary Tract Cancer
- Prostate Cancer
- Urothelial Carcinoma
- Colorectal Cancer
- Triple Negative Breast Cancer
- High Grade Ovarian Serous Adenocarcinoma
- Diffuse Large B Cell Lymphoma
- Renal Cell Cancer Metastatic
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ZM008 | Intravenous delivery |
Timeline
- Start date
- 2024-05-22
- Primary completion
- 2026-12-01
- Completion
- 2027-04-01
- First posted
- 2024-06-11
- Last updated
- 2026-04-02
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06451497. Inclusion in this directory is not an endorsement.